Arbutus Biopharma Corp
ABUS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.0B
$5.15
▲ +0.59%
P/E
6.51
Mkt Cap
$1.0B
52-Wk Range
$3.50–$5.45
52-Week Range
$3.50 - $5.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary GalNAc delivery technology
- Diverse viral treatment pipeline
- Strong strategic research collaborations
- Advanced RNA interference expertise
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Ongoing HBV treatment clinical trials
Value
Trading at 0.3x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+21.5% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 100% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ABUS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.03 vs -$0.02 consensus (-50.0% surprise). Revenue of $1.0M vs $700.0K expected (+44.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-50.0%
Revenue trend · last 8Q
—
-27%
+15%
+522%
-60%
-33%
+10055%
-91%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.3M
$1.6M
$1.8M
$10.7M
$529.0K
$1.1M
$179.1M
$1.0M
Margins · last 8Q
Gross
100.0%
Operating
—
Profit
-507.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ABUS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related